GlassScriptPhysician profile
Sudhhirkumar C Patel
NPI 1962590539
$12,348.28
in general payments reported to CMS, 2019-2025
64 companies · $1,460 in 2025
The $1,460 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,712 · 2020: $2,093 · 2021: $1,995 · 2022: $1,471 · 2023: $2,106 · 2024: $1,512 · 2025: $1,460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,078.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,077.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,497.95 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Astrazeneca Pharmaceuticals LP | $978.58 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $726.72 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $725.67 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $672.04 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $637.05 | 2021-2025 | |
| Lilly USA, LLC | $636.15 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $593.70 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $467.67 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $451.33 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $396.36 | 2019-2023 | |
| Amarin Pharma, INC. | $377.15 | 2019-2022 | |
| Amgen INC. | $371.85 | 2019-2024 | Otezla, Repatha |
| Abbott Laboratories | $324.38 | 2020-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $238.48 | 2019-2024 | Xifaxan, Trulance |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sudhhirkumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.